Highlights from the Quarter (Q1FY27):
Operational Highlights
Vimta Labs reported a decent set of numbers, with income growing by 11.8% yoy. EBITDA margins moderated sequentially due to higher facility-related overheads and the statutory impact of new labor laws/codes. The company has planned a capex of Rs.80 cr, with Rs.10 cr planned for the biologics and the routine capex will be in the tune of Rs.70 cr.
Segmental Breakup
• Pharma Contact Research & Testing Services: Clinical research operations, which faced headwinds in the previous fiscal year, showed encouraging signs of recovery with healthy new inquiry and order inflows. Export revenues accounted for approximately 40% of total revenue, with the US being the primary overseas market
• Biologics Initiative: The company successfully secured its first domestic order for biologics services and operationalized the newly established facility during Q1 FY27. Expected to become a meaningful contributor to top-line and margins from the 3rd year onwards.
• Food testing: Import/export sample receipts declined due to geopolitical trade disruptions and war-related cost escalations in global shipping. Management has successfully mitigated these headwinds by sharpening its focus on domestic market expansion (domestic accounts for ~50% of food testing).
• Electronics & Electrical Testing: Tailwinds are expected from India’s growing focus on quality certification, electronics manufacturing and defence indigenization.
Growth Outlook
Management expects to sustain its growth momentum for FY27, with improvement in growth momentum in the future quarters. Existing lab infrastructure (~200,000 sq. ft. created in Genome Valley, Hyderabad) has sufficient room to support top-line expansion over the next 4–5 years without requiring massive infrastructure expansion.
OUTLOOK AND VALUATION
We We expect the FY28E EPS to be Rs.23.6 and the PAT margin to be 19.6%. We have assigned a P/E multiple of 32X and arrive at a Target Price of Rs. 744, showcasing an upside potential of 24% from current levels with an investment horizon of 18-24 months, with a BUY rating on the stock.